Drug profile · INN
mavorixafor
XOLREMDI
mavorixafor (XOLREMDI) is a c-x-c chemokine receptor type 4 antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — mavorixafor
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L03)
- Route
- ORAL
- Patents
- 10
- Programs
- 7
- Data quality
- 0.84
Quick answer
mavorixafor (XOLREMDI) is a c-x-c chemokine receptor type 4 antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
C-X-C chemokine receptor type 4 antagonist
Primary target: C-X-C chemokine receptor type 4
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Recent coverage
X4 Pharmaceuticals Secures Positive EMA CHMP Opinion for Mavorixafor in WHIM Syndrome
X4 Pharmaceuticals has achieved a significant milestone with a positive opinion from the EMA's CHMP for Mavorixafor, a treatment for WHIM Syndrome. This recommendation moves the company closer to European market entry and has notable implications for the rare disease landscape.
Norgine Receives European Commission Approval for XOLREMDI (Mavorixafor) as First WHIM Syndrome Treatment
Norgine's XOLREMDI becomes first authorized treatment for WHIM syndrome in Europe, marking breakthrough for ultra-rare immunodeficiency patients.
Pipeline programs
Related & competitor drugs
Related patents
-
US 12377090
Methods for treating neutropenia
granted -
US 12285424
Methods for treating neutropenia
granted -
US 12115156
Compositions of CXCR4 inhibitors and methods of preparation and use
granted -
US 11357742
Methods for treating cancer
granted -
US 11337969
Methods for treating cancer
granted -
US 11219621
Methods for treating immunodeficiency disease
granted -
US 11045461
Compositions of CXCR4 inhibitors and methods of preparation and use
granted -
US 10953003
Methods for treating cancer
granted -
US 10610527
Methods for treating immunodeficiency disease
granted -
US 10548889
Compositions of CXCR4 inhibitors and methods of preparation and use
granted
Frequently asked questions
What is mavorixafor?
mavorixafor (XOLREMDI) is a c-x-c chemokine receptor type 4 antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for mavorixafor?
XOLREMDI is a marketed brand name for mavorixafor. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of mavorixafor?
mavorixafor has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.